{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T16:27:55Z","timestamp":1786638475537,"version":"build-2736575974"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008054","name":"Fundaci\u00f3n Ram\u00f3n Areces","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.breast.2020.09.001","type":"journal-article","created":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T02:42:56Z","timestamp":1599792176000},"page":"106-113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["NT-proBNP as predictor factor of cardiotoxicity during trastuzumab treatment in breast cancer patients"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5867-6615","authenticated-orcid":false,"given":"Isabel","family":"Blancas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"Mart\u00edn-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M.","family":"Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Rodr\u00edguez-Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2020.09.001_bib1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.breast.2020.09.001_bib2","doi-asserted-by":"crossref","first-page":"4455","DOI":"10.1002\/cncr.31657","article-title":"Optimal treatment of early stage HER2-positive breast cancer","volume":"124","author":"Pernas","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.breast.2020.09.001_bib3","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13045-019-0798-2","article-title":"Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives","volume":"12","author":"Krasniqi","year":"2019","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.breast.2020.09.001_bib4","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1111\/bph.13643","article-title":"Trastuzumab cardiotoxicity: from clinical trials to experimental studies","volume":"174","author":"Nemeth","year":"2017","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.breast.2020.09.001_bib5","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1471-2407-7-153","article-title":"Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials","volume":"7","author":"Viani","year":"2007","journal-title":"BMC Canc"},{"key":"10.1016\/j.breast.2020.09.001_bib6","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002661","article-title":"Cancer therapy\u2013related cardiac dysfunction and heart failure. Part 1: definitions, pathophysiology, risk factors, and imaging","volume":"9","author":"Bloom","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.breast.2020.09.001_bib7","first-page":"39","article-title":"The role of biomarkers in decreasing risk of cardiac toxicity after cancer therapy","volume":"8","author":"Henri","year":"2016","journal-title":"Biomarkers Canc"},{"key":"10.1016\/j.breast.2020.09.001_bib8","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/jnci\/djs317","article-title":"Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study","volume":"104","author":"Bowles","year":"2012","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.breast.2020.09.001_bib9","first-page":"21","article-title":"Cardiac risk in the treatment of breast cancer: assessment and management","volume":"7","author":"Valachis","year":"2015","journal-title":"Breast Cancer"},{"key":"10.1016\/j.breast.2020.09.001_bib10","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1470-2045(09)70042-7","article-title":"Cardiovascular toxicity caused by cancer treatment: strategies for early detection","volume":"10","author":"Altena","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2020.09.001_bib11","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3747\/co.2008.199","article-title":"Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group","volume":"15","author":"Mackey","year":"2008","journal-title":"Curr Oncol"},{"key":"10.1016\/j.breast.2020.09.001_bib12","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"27","author":"Plana","year":"2014","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.breast.2020.09.001_bib13","doi-asserted-by":"crossref","first-page":"v8","DOI":"10.1093\/annonc\/mdv298","article-title":"Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Senkus","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2020.09.001_bib14","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s11886-012-0256-z","article-title":"Early detection of chemotherapy-related left ventricular dysfunction","volume":"14","author":"DeCara","year":"2012","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.breast.2020.09.001_bib15","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.echo.2005.10.005","volume":"18","author":"Lang","year":"2005","journal-title":"J\u00a0Am Soc Echocardiogr"},{"key":"10.1016\/j.breast.2020.09.001_bib16","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2020.09.001_bib17","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1161\/CIRCULATIONAHA.116.023463","article-title":"Detailed echocardiographic phenotyping in breast cancer patients: associations with ejection fraction decline, recovery, and heart failure symptoms over 3 years of follow-up","volume":"135","author":"Narayan","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.breast.2020.09.001_bib18","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1200\/JCO.2006.09.1611","article-title":"Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial","volume":"25","author":"Suter","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2020.09.001_bib19","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1093\/eurheartj\/ehi631","article-title":"NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study","volume":"27","author":"Januzzi","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.breast.2020.09.001_bib20","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.rce.2016.02.008","article-title":"Documento de consenso y recomendaciones sobre el uso de los p\u00e9ptidos natriur\u00e9ticos en la pr\u00e1ctica cl\u00ednica","volume":"216","author":"Pascual-Figal","year":"2016","journal-title":"Rev Clin Esp"},{"issue":"37","key":"10.1016\/j.breast.2020.09.001_bib21","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"2016","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.breast.2020.09.001_bib22","first-page":"121","article-title":"Diagnosis of chemotherapy-induced cardiotoxicity","volume":"1","author":"Pizzino","year":"2014","journal-title":"J\u00a0Patient Cent Res Rev"},{"key":"10.1016\/j.breast.2020.09.001_bib23","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.jacc.2007.06.037","article-title":"Early breast cancer therapy and cardiovascular injury","volume":"50","author":"Jones","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.breast.2020.09.001_bib24","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ctrv.2010.09.001","article-title":"Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis","volume":"37","author":"Chen","year":"2011","journal-title":"Canc Treat Rev"},{"key":"10.1016\/j.breast.2020.09.001_bib25","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2020.09.001_bib26","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2020.09.001_bib27","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(07)60028-2","article-title":"2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial","volume":"369","author":"Smith","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.breast.2020.09.001_bib28","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10549-014-2836-7","article-title":"Risk of cardiovascular adverse events from trastuzumab (Herceptin\u00ae) in elderly persons with breast cancer: a population-based study","volume":"144","author":"Tsai","year":"2014","journal-title":"Breast Canc Res Treat"},{"key":"10.1016\/j.breast.2020.09.001_bib29","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/djk064","article-title":"Long-term risk of cardiovascular disease in 10-year survivors of breast cancer","volume":"99","author":"Hooning","year":"2007","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.breast.2020.09.001_bib30","article-title":"Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer","volume":"3","author":"Ezaz","year":"2014","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.breast.2020.09.001_bib31","first-page":"507","article-title":"Creating a biomarker panel for early detection of chemotherapy related cardiac dysfunction in breast cancer patients","volume":"8","author":"Srikanthan","year":"2017","journal-title":"J\u00a0Clin Exp Cardiol"},{"key":"10.1016\/j.breast.2020.09.001_bib32","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1200\/JCO.2009.27.3615","article-title":"Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation","volume":"28","author":"Cardinale","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2020.09.001_bib33","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11912-017-0602-9","article-title":"The role of biomarkers in detection of cardio-toxicity","volume":"19","author":"Shah","year":"2017","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.breast.2020.09.001_bib34","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1007\/s13277-015-4183-7","article-title":"Serum biomarkers evaluation to predict chemotherapy-induced cardiotoxicity in breast cancer patients","volume":"37","author":"De Iuliis","year":"2015","journal-title":"Tumor Biol"},{"key":"10.1016\/j.breast.2020.09.001_bib35","doi-asserted-by":"crossref","first-page":"53","DOI":"10.31768\/2312-8852.2015.37(1):53-57","article-title":"The role of cardiac biomarkers as predictors of trastuzumab cardiotoxicity in patients with breast cancer","volume":"37","author":"Urun","year":"2015","journal-title":"Exp Oncol"},{"key":"10.1016\/j.breast.2020.09.001_bib36","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1200\/JCO.2015.65.7916","volume":"35","author":"Zardavas","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2020.09.001_bib37","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1038\/bjc.2011.439","article-title":"Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients","volume":"105","author":"Romano","year":"2011","journal-title":"Br J Canc"},{"key":"10.1016\/j.breast.2020.09.001_bib38","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1743-7563.2012.01588.x","article-title":"Serum NT-proBNP in the early detection of doxorubicin-induced cardiac dysfunction","volume":"9","author":"Kittiwarawut","year":"2013","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.breast.2020.09.001_bib39","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1161\/CIRCIMAGING.112.973321","article-title":"Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab","volume":"5","author":"Sawaya","year":"2012","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.breast.2020.09.001_bib40","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jacc.2013.10.061","article-title":"Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab","volume":"63","author":"Ky","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.breast.2020.09.001_bib41","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1016\/j.jacc.2010.11.063","volume":"57","author":"Fallah-Rad","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.breast.2020.09.001_bib42","first-page":"328","article-title":"Detection of early sub-clinical trastuzumab-induced cardiotoxicity in breast cancer patients","volume":"100","author":"Dores","year":"2013","journal-title":"Arq Bras Cardiol"},{"key":"10.1016\/j.breast.2020.09.001_bib43","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s10549-017-4628-3","article-title":"Cardiac biomarkers for early detection and prediction of trastuzumab and\/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06)","volume":"168","author":"Ponde","year":"2017","journal-title":"Breast Canc Res Treat"},{"key":"10.1016\/j.breast.2020.09.001_bib44","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/annonc\/mdr348","article-title":"Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors","volume":"23","author":"Serrano","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2020.09.001_bib45","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000005195","article-title":"Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: a meta-analysis","volume":"95","author":"Jawa","year":"2016","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.breast.2020.09.001_bib46","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2459\/JCM.0b013e328365afb5","article-title":"Role of hypertension on new onset congestive heart failure in patients receiving trastuzumab therapy for breast cancer","volume":"15","author":"Russo","year":"2014","journal-title":"J\u00a0Cardiovasc Med"},{"key":"10.1016\/j.breast.2020.09.001_bib47","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1200\/JCO.2016.67.4846","article-title":"Obesity as a risk factor for anthracyclines and trastuzumab cardiotoxicity in breast cancer: a systematic review and meta-analysis","volume":"34","author":"Guenancia","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2020.09.001_bib48","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1177\/1078155214567162","article-title":"Risk factors for developing cardiotoxicity of trastuzumab in breast cancer patients: an observational single-centre study","volume":"22","author":"Gunaldi","year":"2016","journal-title":"J\u00a0Oncol Pharm Pract"},{"key":"10.1016\/j.breast.2020.09.001_bib49","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12094-016-1508-y","article-title":"Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study","volume":"19","author":"Gavila","year":"2017","journal-title":"Clin Transl Oncol"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977620301715?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977620301715?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:42:17Z","timestamp":1760776937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977620301715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":49,"alternative-id":["S0960977620301715"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2020.09.001","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NT-proBNP as predictor factor of cardiotoxicity during trastuzumab treatment in breast cancer patients","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2020.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}